The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

BACKGROUND: People with chronic kidney disease (CKD) are at an increased risk of developing hyperkalaemia due to their declining kidney function. In addition, these patients are often required to reduce or discontinue guideline-recommended renin-angiotensin-aldosterone system inhibitor (RAASi) thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Marc, Palaka, Eirini, Furuland, Hans, Bennett, Hayley, Linde, Cecilia, Qin, Lei, McEwan, Phil, Bakhai, Ameet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357372/
https://www.ncbi.nlm.nih.gov/pubmed/30704421
http://dx.doi.org/10.1186/s12882-019-1228-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357372/
https://www.ncbi.nlm.nih.gov/pubmed/30704421
http://dx.doi.org/10.1186/s12882-019-1228-y

Ejemplares similares